TolerRx tolerrx.com


Public lists: Pharma Startups (4732)

TolerRx is discovering, developing, and seeking to commercialize therapies designed to treat patients by reprogramming the immune system, allowing for long-term remission of immune-related diseases - diseases such as diabetes, psoriasis, lupus, and others - after a short course of therapy.

TolerRx is discovering, developing, and seeking to commercialize therapies designed to treat patients by reprogramming the immune system, allowing for long-term remission of immune-related diseases - diseases such as diabetes, psoriasis, lupus, and o...Show all

Company (Dead / Inactive)

Phone: 617-452-1300

Fax:

300 Technology Square
3rd Floor
Cambridge, 02139
Massachusetts, United States

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
TolerRx $124.2M Oct 14, 2011
See all 15 competitors

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related TolerRx Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
See all 25 investors

Competitors

Company Status Description Investors

Amplimmune Immunology

Gaithersburg, Maryland, United States
AcquiredAmplimmune is a product driven company that is developing immune-based biologics to treat patients in the areas of cancer, autoimmunity, transplantation and infectious diseases. Amplimmune's scientific founders from Johns Hopkins University have identified several key immunological ligands and receptors. These immunological checkpoint and co-stimulatory molecules are the basis for developing a new class of biological treatments which modulate critical mechanisms in the body's immune system with ...Show allLogin to see details

Intarcia Therapeutics

Boston, Massachusetts, United States
Alive / ActiveIntarcia Therapeutics is a biopharmaceutical company developing therapies to ensure the best treatment outcome by optimizing patient convenience and adherence. Intarcia is addressing challenging diseases that require long-term chronic therapy by enhancing efficacy and reducing the burden therapies often place on the patient's life. Intarcia's drug development expertise and competitive edge is demonstrated by its ability to stabilize macromolecules and to deliver them in a constant and consistent...Show allLogin to see details
See all 15 competitors

Patents

Title Application Date Patent Date Status
(Patent / Application)
Compositions and methods of tolerizing a primate to an antigen Jul 13, 2006 May 24, 2011 Patent
Gitr-binding antibodies Mar 27, 2006 Oct 12, 2010 Patent
Ilt3 binding molecules and uses therefor Jun 19, 2007 Aug 17, 2010 Patent
Anti-cd4 antibodies Jan 29, 2003 Jun 02, 2009 Patent